0922 deals qt
BioCentury & Getty Images


Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

Sep 23, 2020 | 1:20 AM GMT

Priority Review for bluebird-BMS program could fulfill CVR goal
FDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc. (NASDAQ:BLUE) and Bristol Myers Squibb

Read the full 564 word article

How to gain access

Continue reading with a
two-week free trial.